Cmv lead to pneumonia in infants

Reading File

Finding Sources

Searching PubMed

cytomegalovirus pneumonia infants

Reading File

Finding Sources

Reading File

I now have comprehensive data. Let me compile the full answer.

CMV and Pneumonia in Infants

Cytomegalovirus (CMV) is a beta-herpesvirus (human herpesvirus 5) and is the most common congenital viral infection in the United States, affecting approximately 5 per 1,000 live births. Its relationship to pneumonia in infants depends heavily on the timing of acquisition and the infant's gestational age and immune status.

How CMV Is Acquired in Infants

CMV reaches infants through three routes:

In utero (congenital) - transplacental transmission of maternal bloodborne virus; most damaging when acquired in the first trimester
Intrapartum - passage through an infected maternal genital tract
Postpartum (perinatal) - ingestion of CMV-positive human milk, or via transfusion from CMV-seropositive donors

CMV Pneumonia in Infants: Who Is at Risk?

Term infants who acquire CMV from breast milk or cervical secretions generally do NOT develop clinical illness, likely because of passively transferred maternal antibody.

Preterm infants are the key at-risk group. Specifically, infants born before 32 weeks' gestation with birth weight under 1,500 g are at significantly greater risk of CMV disease. In this population, postpartum infection from human milk or transfusion from CMV-seropositive donors has been associated with:

Interstitial pneumonia (the primary pulmonary manifestation)
Hepatitis
Hematologic abnormalities (thrombocytopenia, leukopenia)
A viral sepsis-like syndrome

This is documented in the Red Book 2021, which states: "postpartum infection resulting from human milk or from transfusion from CMV-seropositive donors has been associated with hepatitis, interstitial pneumonia, hematologic abnormalities including thrombocytopenia and leukopenia, and a viral sepsis syndrome."

Pulmonary Pathogenesis

CMV infects fibroblasts, epithelial cells, endothelial cells, and smooth muscle cells in the lung. Infected cells develop large basophilic intranuclear inclusions ("owl-eye" inclusions) - the histologic hallmark. Two histopathologic patterns can occur in the lung:

Miliary pattern - multiple focal lesions with cytomegaly, localized necrosis, alveolar hemorrhage, fibrin deposition, and neutrophilic infiltrate
Interstitial pattern - alveolar cell hyperplasia, interstitial edema, lymphoid infiltration, and diffusely distributed cytomegalic cells

The pathogenesis has both a direct viral replication component and an immunopathologic component.

Murray & Nadel's Textbook of Respiratory Medicine, p. (block 10)

Congenital CMV Disease (Symptomatic at Birth)

About 10% of congenitally infected infants are symptomatic at birth. Classic features include:

Jaundice (direct hyperbilirubinemia)
Petechiae/purpura (thrombocytopenia)
Hepatosplenomegaly
Microcephaly
Periventricular calcifications
Retinitis
Sensorineural hearing loss (SNHL) - the most common long-term sequela

Pneumonia per se is not a dominant feature of congenital CMV disease in term infants; it is more characteristic of the preterm/postnatal-acquisition scenario.

Diagnosis

PCR (quantitative) on blood, urine, or BAL fluid is the preferred method - sensitive, standardized, rapid
Urine culture or saliva PCR within the first 3 weeks of life confirms congenital infection
BAL detection of CMV in bronchoalveolar lavage supports pulmonary disease, though CMV shedding without disease must be differentiated
Recovery of virus from a target organ (e.g., lung biopsy showing inclusions) provides the strongest evidence of CMV as the causative agent
Red Book 2021 - Report of the Committee on Infectious Diseases

Treatment

For infants with symptomatic congenital CMV disease (including those with significant organ involvement):

Valganciclovir (oral, preferred) or ganciclovir (IV for severe disease) for 6 months
Antiviral therapy is shown to improve hearing outcomes and neurodevelopmental outcomes
Treatment indication in preterm infants with CMV pneumonia is assessed case-by-case; severe or progressive disease generally warrants treatment

Summary Table

Population	Risk of CMV Pneumonia	Mechanism
Term infant (intrapartum/breast milk)	Very low	Maternal antibody protection
Preterm (<32 wk, <1500 g) via breast milk/transfusion	Significant	Immature immune system, low maternal antibody
Symptomatic congenital CMV (10% of infected)	Uncommon feature	Systemic dissemination
Immunocompromised infant	High	Impaired viral clearance

CMV pneumonia in infants is almost always an interstitial pneumonia, and in the neonatal/infant period it is most clinically significant in very preterm infants. It should be considered in any preterm infant with unexplained respiratory deterioration, thrombocytopenia, and hepatitis, especially if the mother is CMV-seropositive and the infant was breastfed or received blood transfusions.

This is a shared conversation. Sign in to Orris to start your own chat.